Interestingly, VEGFR2 and Ephs represent two promising objectives for the development of multitarget drugs, as they are expressed in both cancer and ECs and are involved in tumor cell proliferation, metastatization [50–52], and neovascularization [4–6]. The gene discussed is KDR; the disease is neoplasm.